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Dear Editor,
We would like to thank Rouvas et al. for their interest in our
article regarding the role of ranibizumab in the treatment of
retinal angiomatous proliferation (RAP) [1].
Rouvas et al. evaluated in a very interesting recent
publication the role of different treatment modalities on
RAP [2]. Their study is an excellent contribution to a still
challenging issue regarding optimal treatment of RAP.
In our article, we highlighted some differences between
the two studies. We consider that constructive discussions
can be triggered by contrasting differences in the two
studies that may help us to get a better insight regarding
various aspects of the challenging treatment of RAP, even if
firm conclusions cannot be drawn.
We agree with Rouvas et al. that the two studies, which
were performed in different medical centers with different
methodology and included subjects with different character-
istics, cannot be compared in a statistically reliable way.
We are both agreed that when OCT alone is used to
dictate treatment in cases of RAP with PED, as happened in
both studies, there is a chance of patients having missed
treatment. We are also both agreed that the difference in the
percentage of patients presenting pigment epithelium
detachment (PED) at baseline between the two studies is
probably of significance.
Although we consider that it is interesting to point out
these differences, it is not known whether they could have
influenced the divergence in results between the two studies.
Our study is currently the largest study that evaluated the
role of ranibizumab in the treatment of RAP lesions.
However, RAP includes a wide range of different clinical
manifestations, and consequently, a study that could
provide a high level of scientific evidence should include
a significant number of patients.
Until a large-scale randomized, long-term clinical trial
establishes more accurately the potential clinical benefit of
intravitreal ranibizumab versus other therapeutic modalities,
the debate regarding the optimal treatment of RAP is ongoing.
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